Clinical trial

Ceritinib Plus Docetaxel in ALK-Negative, EGFR WT Advanced NSCLC

NCT03611738

StatusACTIVE_NOT_RECRUITING

Study typeINTERVENTIONAL

Start date2019-02-01

PhasePHASE1

Study timeline

Study start (actual)2019-02-01Date precision: day

Registry last updated2026-05-15

Observed by CureCurrent2026-10-07

Recorded dates are source observations, not predictions. Missing milestones are not estimated.

Conditions

Non-small Cell Lung Cancerunresolved

Lung Cancerunresolved

Non-small Cell Lung Cancer Metastaticunresolved

Non-small Cell Lung Cancer Stage IIIBunresolved

Stage IV Non-small Cell Lung Cancerunresolved

EGFR Negative Non-Small Cell Lung Cancerunresolved

Interventions

CeritinibDRUG · verified · RxNorm: ceritinib

DocetaxelDRUG · verified · RxNorm: docetaxel

Sponsors & collaborators

H. Lee Moffitt Cancer Center and Research Institutelead sponsor

Mapped research locations

TampaFlorida, United States1 OrlandoFlorida, United States1

Registry source

Open the source record to verify current eligibility, contacts, locations and registry updates.

Open NCT03611738 on ClinicalTrials.gov ↗

Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.